https://investors.phasebio.com/ PhaseBio Pharmaceuticals, Inc. News Releases en https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-interim-analysis-reverse-it-phase-3-trial MALVERN, Pa. & SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that REVERSE-IT ( R apid and Sustain Wed, 06 Oct 2021 08:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8316 https://investors.phasebio.com/news-releases/news-release-details/phasebio-appoints-william-d-humphries-board-directors MALVERN, Pa. & SAN DIEGO --(BUSINESS WIRE)--Sep. 15, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Wed, 15 Sep 2021 08:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8206 https://investors.phasebio.com/news-releases/news-release-details/phasebio-pharmaceuticals-present-23rd-annual-hc-wainwright MALVERN, Pa. & SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Tue, 31 Aug 2021 16:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8186 https://investors.phasebio.com/news-releases/news-release-details/phasebio-reports-second-quarter-2021-financial-results-and Entered exclusive licensing agreement with Alfasigma S.p.A with up to $245 million in milestone payments and tiered royalty payments for development and commercialization of bentracimab in European and other key markets Achieved interim enrollment milestone with first 143 bentracimab patients Thu, 12 Aug 2021 08:30:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8151 https://investors.phasebio.com/news-releases/news-release-details/phasebio-pharmaceuticals-achieves-enrollment-milestones First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focus shifting to enrollment of patients with Thu, 12 Aug 2021 08:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8146 https://investors.phasebio.com/news-releases/news-release-details/phasebio-pharmaceuticals-and-sfj-pharmaceuticalsr-announce Enrollment in the REVERSE-IT global Phase 3 trial from clinical sites in China expected to begin later in 2021 MALVERN, Pa. & SAN DIEGO --(BUSINESS WIRE)--Aug. 10, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and Tue, 10 Aug 2021 08:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8136 https://investors.phasebio.com/news-releases/news-release-details/phasebio-pharmaceuticals-present-william-blair-biotech-focus MALVERN, Pa. & SAN DIEGO --(BUSINESS WIRE)--Jun. 30, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Wed, 30 Jun 2021 16:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8106 https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-european-licensing-agreement-alfasigma-spa Agreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab opportunity Establishes accessibility to bentracimab, Thu, 17 Jun 2021 08:00:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8091 https://investors.phasebio.com/news-releases/news-release-details/phasebio-highlights-real-world-healthcare-cost-and-bleeding-cost Study leveraging the IBM® MarketScan® claims database examined healthcare resource utilization including total healthcare costs and bleeding costs in patients initiating P2Y 12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y 12 inhibitors incurred total costs Thu, 20 May 2021 16:30:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8016 https://investors.phasebio.com/news-releases/news-release-details/phasebio-highlights-real-world-bleeding-and-surgery-data Study leveraging the IBM® MarketScan® claims database examined bleeding events and rates of surgical procedures in patients initiating P2Y 12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y 12 inhibitors had a higher burden of significant comorbid conditions Mon, 17 May 2021 16:30:00 -0400 PhaseBio Pharmaceuticals, Inc. News Releases 8006